Cue Biopharma (CUE) Receivables - Net (2019 - 2025)
Cue Biopharma (CUE) has disclosed Receivables - Net for 7 consecutive years, with $5.5 million as the latest value for Q4 2025.
- Quarterly Receivables - Net rose 486.88% to $5.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2025, up 486.88% year-over-year, with the annual reading at $5.5 million for FY2025, 486.88% up from the prior year.
- Receivables - Net hit $5.5 million in Q4 2025 for Cue Biopharma, up from $387000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $5.5 million in Q4 2025 to a low of $57000.0 in Q4 2022.
- Historically, Receivables - Net has averaged $1.5 million across 5 years, with a median of $1.1 million in 2023.
- Biggest five-year swings in Receivables - Net: crashed 98.19% in 2022 and later surged 2878.95% in 2023.
- Year by year, Receivables - Net stood at $3.1 million in 2021, then crashed by 98.19% to $57000.0 in 2022, then soared by 2878.95% to $1.7 million in 2023, then crashed by 44.35% to $945000.0 in 2024, then skyrocketed by 486.88% to $5.5 million in 2025.
- Business Quant data shows Receivables - Net for CUE at $5.5 million in Q4 2025, $387000.0 in Q3 2025, and $532000.0 in Q2 2025.